IDEXX Laboratories, Inc. $IDXX Shares Sold by SYM FINANCIAL Corp

SYM FINANCIAL Corp cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52.4% during the third quarter, Holdings Channel reports. The firm owned 877 shares of the company’s stock after selling 967 shares during the quarter. SYM FINANCIAL Corp’s holdings in IDEXX Laboratories were worth $560,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. STF Management LP raised its holdings in IDEXX Laboratories by 1.3% during the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after buying an additional 16 shares during the period. Clearstead Trust LLC increased its position in shares of IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after acquiring an additional 16 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after acquiring an additional 16 shares during the period. Moss Adams Wealth Advisors LLC lifted its position in shares of IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after acquiring an additional 17 shares in the last quarter. Finally, Stratos Wealth Partners LTD. lifted its position in shares of IDEXX Laboratories by 1.7% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock valued at $564,000 after acquiring an additional 18 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 1.6%

Shares of IDXX stock opened at $676.71 on Friday. The stock’s 50 day simple moving average is $706.46 and its 200 day simple moving average is $658.91. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98. The company has a market capitalization of $54.04 billion, a price-to-earnings ratio of 53.66, a PEG ratio of 3.67 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $2.80 EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Morgan Stanley lifted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. UBS Group upped their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.